BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q1 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,846,465 | -39.5% | 422,572 | -26.8% | 0.03% | -41.1% |
Q2 2023 | $26,177,664 | +14.2% | 577,109 | +1.5% | 0.06% | +12.0% |
Q1 2023 | $22,914,582 | +422.7% | 568,459 | +557.9% | 0.05% | +400.0% |
Q4 2022 | $4,383,885 | -50.4% | 86,399 | -47.4% | 0.01% | -54.5% |
Q3 2022 | $8,839,000 | +18.2% | 164,104 | +41.0% | 0.02% | +29.4% |
Q2 2022 | $7,478,000 | -63.3% | 116,427 | -55.6% | 0.02% | -56.4% |
Q1 2022 | $20,354,000 | -55.1% | 262,497 | -50.2% | 0.04% | -52.4% |
Q4 2021 | $45,283,000 | +2.8% | 527,524 | -3.7% | 0.08% | 0.0% |
Q3 2021 | $44,042,000 | -17.0% | 547,581 | -16.9% | 0.08% | -10.9% |
Q2 2021 | $53,065,000 | -30.8% | 659,198 | -27.5% | 0.09% | -26.4% |
Q1 2021 | $76,644,000 | -9.9% | 908,745 | -15.1% | 0.12% | -17.2% |
Q4 2020 | $85,069,000 | -5.3% | 1,069,776 | -5.7% | 0.15% | -0.7% |
Q3 2020 | $89,855,000 | -27.8% | 1,134,527 | -23.2% | 0.15% | -24.4% |
Q2 2020 | $124,522,000 | -10.7% | 1,478,007 | -13.9% | 0.20% | -14.1% |
Q1 2020 | $139,394,000 | -26.2% | 1,716,882 | -24.2% | 0.23% | +8.8% |
Q4 2019 | $188,980,000 | -30.4% | 2,264,868 | -27.4% | 0.22% | -32.8% |
Q3 2019 | $271,677,000 | -8.1% | 3,119,499 | -14.0% | 0.32% | -3.0% |
Q2 2019 | $295,611,000 | -9.5% | 3,627,140 | -10.5% | 0.33% | -4.9% |
Q1 2019 | $326,698,000 | -2.9% | 4,051,820 | -20.7% | 0.35% | -11.0% |
Q4 2018 | $336,403,000 | -34.7% | 5,110,957 | -23.6% | 0.39% | -20.9% |
Q3 2018 | $515,449,000 | +2.7% | 6,686,334 | -1.5% | 0.49% | -2.6% |
Q2 2018 | $502,094,000 | +41.0% | 6,787,947 | +24.0% | 0.51% | +31.8% |
Q1 2018 | $355,997,000 | -8.6% | 5,473,510 | -9.1% | 0.38% | -6.1% |
Q4 2017 | $389,422,000 | +7.5% | 6,024,474 | +4.3% | 0.41% | -5.3% |
Q3 2017 | $362,416,000 | +4.9% | 5,775,540 | +1.2% | 0.43% | -5.5% |
Q2 2017 | $345,550,000 | +19.2% | 5,707,805 | +2.1% | 0.46% | +18.7% |
Q1 2017 | $289,826,000 | -3.8% | 5,588,610 | -17.8% | 0.38% | -7.5% |
Q4 2016 | $301,302,000 | +24.7% | 6,795,261 | +33.8% | 0.42% | +12.4% |
Q3 2016 | $241,705,000 | +85.3% | 5,077,842 | +76.0% | 0.37% | +60.9% |
Q2 2016 | $130,475,000 | +27.1% | 2,885,352 | +15.5% | 0.23% | +24.3% |
Q1 2016 | $102,665,000 | +84.9% | 2,499,135 | +71.8% | 0.18% | +90.7% |
Q4 2015 | $55,511,000 | +389.8% | 1,455,080 | +321.8% | 0.10% | +321.7% |
Q3 2015 | $11,333,000 | +97.9% | 344,986 | +321.3% | 0.02% | +109.1% |
Q2 2015 | $5,726,000 | +32.0% | 81,883 | +29.3% | 0.01% | +10.0% |
Q1 2015 | $4,337,000 | +7.3% | 63,311 | +14.8% | 0.01% | +25.0% |
Q4 2014 | $4,041,000 | +67.5% | 55,137 | +64.0% | 0.01% | +14.3% |
Q3 2014 | $2,412,000 | -44.9% | 33,611 | -44.5% | 0.01% | -41.7% |
Q2 2014 | $4,375,000 | +136.4% | 60,511 | +140.5% | 0.01% | +100.0% |
Q1 2014 | $1,851,000 | -84.4% | 25,157 | -85.3% | 0.01% | -82.9% |
Q4 2013 | $11,886,000 | -64.6% | 170,899 | -66.5% | 0.04% | -70.3% |
Q3 2013 | $33,539,000 | -35.0% | 510,572 | -31.5% | 0.12% | -35.5% |
Q2 2013 | $51,634,000 | +459.1% | 745,408 | +438.1% | 0.18% | +357.5% |
Q4 2012 | $9,235,000 | – | 138,532 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |